Advancing Risk-Informed Breast Cancer Screening: Development of a Digital Toolkit for Primary Care and OB/GYN Integration

Melissa Thomas, PhD, MSPH, MSA, MCHES®, CCHW[1]; Amanda Woodworth, MD, FACS, FSSO, CPE[2]; Aditi Hazra, PhD, MPH[3]; Lilly Meier, MA[1]; Sarah Shafir, MPH[1]

[1]American Cancer Society, Atlanta, GA; [2]Keck School of Medicine, University of Southern California, Los Angeles, CA; [3]VA Boston Healthcare System & Harvard Medical School, Boston, MA

Abstract #1312

Background

- Risk-informed breast cancer screening helps identify individuals who may benefit from earlier, more frequent, or more intensive screening (e.g., MRI) and/or genetic counseling.
- Despite strong evidence, implementation of breast cancer risk assessment in primary care and OB/GYN settings remains limited.

Barriers commonly cited in the literature include:



Lack of provider familiarity with available models | Workflow disruption and time constraints | EHR integration challenges | Inconsistent guidance on which tool to use for which patient

- To address these gaps, the American Cancer Society National Breast Cancer Roundtable (ACS NBCRT) developed a digital Breast Cancer Risk Assessment Toolkit.
- The toolkit aims to support guideline-aligned, equitable, and consistent implementation of breast cancer risk assessment in routine care.

Methods

- Toolkit development was led by the ACS NBCRT Early Action Priority Team with a multidisciplinary Advisory Group, including primary care, breast oncology, public health, health equity.
- A rigorous development process included:
  - Guideline-anchored literature review (ACS, NCCN, USPSTF)
  - Structured PubMed search comparing widely used risk models
  - Classification of tools based on inputs, outputs, target populations, family history depth, risk horizon, and appropriateness for diverse clinical settings
  - Integration of evidence on risk communication and shared decision-making

METHODS WORKFLOW



Literature review
Reviewed breast cancer risk models and guideline-based implementation evidence (ACS, NCCN, USPSTF).

Framework development
Developed model comparison structure and six-domain readiness assessment

Toolkit design
Drafted clinical workflow, checklist, provider scripts, and EHR integration outline

Multidisciplinary feedback
Refined content with input from primary care, breast oncology, public health, and equity stakeholders

Refinement & finalization
Aligned tools with ACS guidance and equity priorities; prepared for disseminatiom

Results

Toolkit development outputs



A clinical workflow aligning risk assessment results with next steps in screening and genetic counseling | A standardized checklist to support consistent use of validated models | Provider communi-cation scripts to facilitate clear, culturally responsive discussions | A health system readiness assessment outlining organiza-tional workflows | A model comparison framework summarizing scope, requirements and risk horizons for commonly used tools | An equity case study (Tu Historia Cuenta) demonstrating community-engaged risk-assessment

Toolkit Integration Across Clinical, Technical, and Equity Domains

Key insights included:


- **Clinical workflow**: Risk assessment must be embedded into routine visits with clear next steps for screening and genetic counseling.
- **Staff preparation:** Teams need role-specific scripts, prompts, and checklists to support consistent implementation.
- **Data & documentation:** Validated models are only effective when supported by reliable data capture, structured fields, and actionable EHR documentation pathways.
- **Organizational readiness**: Practices vary widely in infrastructure, staffing, and leadership engagement—requiring flexible, modular tools.
- **Equity integration**: Literacy, language, and cultural context must be considered at every stage to ensure equitable uptake and reduce disparities in access to risk-informed care.

Discussion

Challenges Identified During Development

- Fragmented guidance on which model to use for which patient scenario.
- Inconsistent incorporation of family history, density, and hereditary risk factors in primary care workflows.
- Lack of standardized processes for documenting and acting on risk estimates in EHR systems.
- Insufficient tools to support shared decision-making and patient-centered conversations.
- Significant variation in organizational capacity, highlighting the need for a readiness framework.
- Equity gaps in uptake of risk assessment and genetic counseling, especially among Spanish-speaking and underrepresented populations.

Results



Breast Cancer Clinic Workflow

Breast Cancer Risk Assessment Clinic Workflow

This resource was developed by the American Cancer Society National Breast Cancer Roundtable (ACS NBCRT) to support providers in conducting breast cancer risk assessment. The chart illustrates a typical clinic workflow for breast cancer risk assessment, highlighting key decision points around screening, risk assessment, and genetic counseling referral. See the digital toolkit for more breast cancer risk assessment resources.

Conclusions

- The ACS NBCRT Digital Breast Cancer Risk Assessment Toolkit provides a scalable, equity-oriented solution to longstanding implementation gaps in risk-informed breast cancer care..
- Resources are designed for **real-world feasibility** across primary care, OB/GYN, and community-engaged settings.
- Future directions include:
  - Expansion of case studies to represent rural, safety-net, and diverse populations
  - Dissemination through ACS NBCRT partners
  - Practice-based implementation and evaluation to assess feasibility, acceptability, workflow impact, and clinical outcomes

Acknowledgements

We grateful acknowledge the Early Action Priority Team Advisory Group members for their expertise and guidance: Ysabel Duron, BA; Amy Patel, MD; Carlton Allen, MS, CHW, CHES®; Captain Jacqueline Miller, MD, FACS; Lisa Schlager, BA; and Lisa Soltani, MD, MPH, FACP.

Contact

ACS NBCRT Risk Assessment Toolkit

Melissa Thomas, PhD, MSPH, MSA, MCHES®, CCHW
Strategic Director, ACS National Breast Cancer Roundtable
Melissa.Thomas@cancer.org